Brief Report

Pregnancy Outcome Following Maternal Use of the New Selective Serotonin Reuptake Inhibitors

A Prospective Controlled Multicenter Study

Nathalie A. Kulin, MSc; Anne Pastuszak, MSc; Suzanne R. Sage, RN, MS; Betsy Schick-Boschetto, MSN; Glenda Spivey, MS, CT; Marcia Feldkamp; Kelly Ormond, MS; Doreen Matsui, MD; Amy K. Stein-Schechman, MS; Lola Cook, MS; Joanne Brochu; Michael Rieder, MD; Gideon Koren, MD

Context.—Although a large number of women of reproductive age use new selective serotonin reuptake inhibitors (SSRIs) and half of all pregnancies are unplanned, no data exist on the safety of these agents for the human fetus.

Objective.—To assess fetal safety and risk of fluvoxamine, paroxetine, and sertraline.

Design.—A prospective, multicenter, controlled cohort study.

Setting.—Nine Teratology Information Service centers in the United States and Canada.

Patients.—All women who were counseled during pregnancy following exposure to a new SSRI and followed up by the participating centers. Controls were randomly selected from women counseled after exposure to nonteratogenic agents.

Main Outcome Measures.—Rates of major congenital malformations.

Results.—A total of 267 women exposed to an SSRI and 267 controls were studied. Exposure to SSRIs was not associated with either increased risk for major malformations (9/222 live births [4.1%] vs 9/235 live births [3.8%] in the controls; relative risk, 1.06; 95% confidence interval, 0.43-2.62) or higher rates of miscarriage, stillbirth, or prematurity. Mean (SD) birth weights among SSRI users (3439 [505] g) were similar to the controls (3445 [610] g) as were the gestational ages (39.4 [1.7] weeks vs 39.4 [1.9] weeks).

Conclusion.—The new SSRIs, fluvoxamine, paroxetine, and sertraline, do not appear to increase the teratogenic risk when used in their recommended doses.

A DECADE after the introduction of the first selective serotonin reuptake inhibitor (SSRI), fluoxetine, into clinical use, this class of antidepressants is being used by millions of men and women worldwide. Because more than half of all pregnancies are unplanned1 and an estimated 5% to 20% of all women suffer from depression,2 fetal safety is a primary concern. During the last decade, several studies have reported on pregnancy outcome following first-trimester or whole-pregnancy exposure to fluoxetine. Although there was no evidence of major malformations or behavioral teratology,3,4 women who took fluoxetine throughout pregnancy had more perinatal complications and more minor malformations,5 possibly as a result of risks associated with more severe depression.

During the last few years new SSRIs have been introduced into the market.6 Currently, while a large number of women of reproductive age use newer SSRIs for depression and other indications (such as obsessive compulsive disorder),7 no human data on their reproductive safety exist.

Animal teratology studies with fluvoxamine (up to 80 mg/kg per day),6 paroxetine (up to 43 mg/kg per day),8 and sertraline (up to 80 mg/kg per day)9 have failed to show an increased risk of fetal dysmorphology or other perinatal complications. Spontaneous reports to the manufacturers are sparse and include both retrospective and prospective cases with no controls, precluding the ability to estimate fetal risk.

We report on the first prospective, controlled, cohort study of pregnancy outcome following fetal exposure to the new SSRIs.

Patients and Methods

This prospective cohort included all women who contacted one of nine participating Teratology Information Service centers regarding exposure to fluvoxamine, paroxetine, and sertraline during the first trimester of pregnancy for depression. Excluded were women who, in addition to being exposed to a new SSRI, were also exposed to a known human teratogen or drugs of uncertain teratogenicity. The group exposed to SSRIs was matched to controls who were randomly selected from the total group of women counseled and followed by the Motherisk Program after exposure to agents proven to be nonteratogenic (e.g., dental x-rays, acetylsalicylic acid).

During the initial interview at the time of exposure, women were asked about a variety of health-related issues including diagnosis; SSRI dose schedule and length of therapy; other drug therapy; recreational drug use; cigarette and alcohol consumption; past medical, obstetric, and genetic history; and exposure to environmental toxins. After the expected date of confinement, women were contacted and interviewed regarding the course of pregnancy, pregnancy outcome, and neonatal health. In most cases, these interviews were conducted 6 to 9 months after delivery. Reports of major malformations were corroborated with medical records.

The primary end point of interest was the rates of major malformations, de-
controls, selective serotonin reuptake inhibitors (SSRIs) vs.

Table 1.—Maternal Demographics: Exposed to an SSRI vs. Controls

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Exposed to SSRIs, No. (%)</th>
<th>Controls, No. (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>31.3 (4.7)</td>
<td>30.8 (4.9)</td>
<td>.29</td>
</tr>
<tr>
<td>Parity</td>
<td>15 7 9 0</td>
<td>15 7 9 0</td>
<td></td>
</tr>
<tr>
<td>Gravida</td>
<td>1 152 142</td>
<td>1 152 142</td>
<td></td>
</tr>
<tr>
<td>Previous spontaneous abortion</td>
<td>157 205</td>
<td>49 61</td>
<td>.91</td>
</tr>
<tr>
<td>Tobacco consumption</td>
<td>166 235</td>
<td>40 31</td>
<td>.03</td>
</tr>
<tr>
<td>Alcohol consumption</td>
<td>74 43</td>
<td>129 224</td>
<td>.001</td>
</tr>
<tr>
<td>Maternal age at conception, mean (SD)</td>
<td>31.3 (4.7)</td>
<td>30.8 (4.9)</td>
<td>.29</td>
</tr>
</tbody>
</table>

*aMaternal age was unknown for 4 SSRI cases.

Table 2.—Pregnancy Outcome: Exposed to Selective Serotonin Reuptake Inhibitors (SSRIs) vs. Controls

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Exposed to SSRIs, No. (%)</th>
<th>Controls, No. (%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Live births</td>
<td>222 235</td>
<td>142 142</td>
<td>.14</td>
</tr>
<tr>
<td>Spontaneous abortions</td>
<td>30 21</td>
<td>50 50</td>
<td>.24</td>
</tr>
<tr>
<td>Therapeutic abortions</td>
<td>15 9</td>
<td>15 9</td>
<td>.30</td>
</tr>
<tr>
<td>Stillbirths</td>
<td>0 2</td>
<td>0 2</td>
<td></td>
</tr>
<tr>
<td>Major malformations</td>
<td>9 9</td>
<td>9 9</td>
<td>.91</td>
</tr>
<tr>
<td>Birth weight, mean (SD), g</td>
<td>3439 (505)</td>
<td>3445 (610)</td>
<td>.91</td>
</tr>
<tr>
<td>Gestational age, mean (SD), wk</td>
<td>39.4 (1.7)</td>
<td>39.4 (1.9)</td>
<td>.71</td>
</tr>
</tbody>
</table>

Table 3.—Number of Major Malformations in the Selective Serotonin Reuptake Inhibitor (SSRI) and Control Groups

<table>
<thead>
<tr>
<th>Malformation</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double urinary collecting system</td>
<td>2</td>
</tr>
<tr>
<td>Cardiac malformations</td>
<td>2</td>
</tr>
<tr>
<td>Absent corpus callosum</td>
<td>1</td>
</tr>
<tr>
<td>Bilateral club foot</td>
<td>1</td>
</tr>
<tr>
<td>Ear malformation</td>
<td>1</td>
</tr>
<tr>
<td>Ovarian cysts</td>
<td>1</td>
</tr>
<tr>
<td>Pyloric stenosis</td>
<td>1</td>
</tr>
<tr>
<td>Control group</td>
<td></td>
</tr>
<tr>
<td>Cardiac malformations</td>
<td>4</td>
</tr>
<tr>
<td>Inguinal hernia</td>
<td>2</td>
</tr>
<tr>
<td>Undescended testicle</td>
<td>1</td>
</tr>
<tr>
<td>Ecopic kidney</td>
<td>1</td>
</tr>
<tr>
<td>Vesicourethral reflux</td>
<td>1</td>
</tr>
</tbody>
</table>

defined as structural or functional anomalies that have significant medical or social consequences. The SSRIs and control groups were compared on a variety of baseline characteristics and pregnancy outcome values using the unpaired t test (for continuous variables) or the Fisher exact test (for proportions).

Results

A total of 267 women met the study inclusion criteria (92 from Toronto, Ontario; 66 from Tampa, Fla; 46 from Philadelphia, Pa; 32 from Farmington, Conn; 11 from Salt Lake City, Utah; 7 from Burlington, Vt; 6 from London, Ontario; 4 from Chicago, Ill; and 3 from Indianapolis, Ind). A total of 147 women used sertraline, 97 used paroxetine, and 26 used fluvoxamine. One woman used both sertraline and fluoxetine, and 2 women used paroxetine and sertraline in the first trimester. The 267 women exposed to an SSRI, 49 used the drug throughout pregnancy. Whether the new SSRIs are safe for their unborn fetuses.

Typically, women are excluded from premarketing clinical trials as it is perceived to be medically unethical to test drugs during human pregnancy. This results in a lack of fetal safety information on introduction of the drug into the market, and the SSRIs are not an exception.

Our study confirms animal experiments by showing that when used in the recommended doses, the new SSRIs do not appear to increase the risk of congenital malformations. Our sample size was large enough to detect a relative risk of 2.5 for major malformations with a power of 80% and an α of .05. However, the absolute rates (92/267 vs 92/267) between the SSRIs and control groups implies that thousands more cases in each group would not change this result. Our results on all measured pregnancy outcomes are well within those reported in the general population.

Our study was not designed to address potential behavioral teratology of SSRIs. A recent study with fluoxetine failed to find differences in IQ, language, and behavior after fetal exposure to the drug. Recent findings of more minor malformations and perinatal complications among infants exposed to fluoxetine throughout pregnancy are difficult to interpret because the study did not control for depression. When controlled for depression with a group exposed to tricyclic antidepressants, infants exposed to fluoxetine in utero do not appear to have more minor malformations or perinatal complications (I. Nulman, written communication, October 1, 1997).

In summary, this study indicates that the new SSRIs, fluvoxamine, paroxetine, and sertraline do not appear to increase the teratogenic risk when used in their recommended doses.

References